iShares Biotechnology ETF (IBB)
Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
I Was Convinced Biotech Stocks Were Too Risky—This Innovation's Changing the Game
The biotech scene can be seen as fairly risky for new investors who want to put money to work.
Why Biotech Sector ETF (IBB) May Turn Bullish In 2025
One of the big themes we see emerging into 2025 is an expansion in Biotechnology and a bullish backdrop for certain biotechnology stocks.
iShares Biotechnology ETF: Playing Defense
The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is returning to the biotech sector as displayed by increased M&A activity and financing following the pandemic-driven bubble in the sector. Biotech is a blooming area of innovation and US productivity and is expected to grow at a 14% CAGR over the next decade.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Is Biotech's Bull Run Over? Examining Election Impacts
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.
Final Trade: Euro, IBB, SMH, NEM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral
I reiterate a hold rating on IBB due to its stretched valuation at nearly 20x earnings and mixed technical situation. Despite a 7% YTD gain, IBB has underperformed the S&P 500, which is up 21%, and shows negative alpha. Key support and resistance levels to watch are $138-$141 and $150, respectively, with a potential bullish move to $160.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Making its debut on 02/05/2001, smart beta exchange traded fund iShares Biotechnology ETF (IBB) provides investors broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.
